Yüklüyor......
Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO(®) (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers
BACKGROUND: HCP1004 is a newly developed fixed-dose combination of naproxen (500 mg) and esomeprazole strontium (20 mg) that is used in the treatment of rheumatic diseases and can reduce the risk of nonsteroidal anti-inflammatory drug-associated ulcers. The aim of this study was to evaluate the phar...
Kaydedildi:
| Yayımlandı: | Drug Des Devel Ther |
|---|---|
| Asıl Yazarlar: | , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Dove Medical Press
2015
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4527374/ https://ncbi.nlm.nih.gov/pubmed/26257511 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S86725 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|